Latest Conference Articles

Research presented by Jalpa A. Doshi, PhD, associate professor of medicine, director, Economic Evaluations Unit, Center for Evidence-based Practice, and director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Presentation by Marcia Baker, MS, Ed, director, Corporate Development & Programs, Mended Hearts, Inc, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Presentation by Andrea Baer, MS, director of Patient Advocacy, Mended Hearts, Inc, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Work presented by Veena Shankaran, MD, MS, associate professor, Division of Medical Oncology, University of Washington and associate member, Clinical Research Division, Fred Hutchinson Cancer Research Center, at the the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Melissa Thompson, MBA, healthcare strategist and a cancer patient, spoke at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Tricia Neuman, senior vice president of the Henry J. Kaiser Family Foundation and director of the Foundation’s Program of Medicare Policy, was the guest speaker at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care.

Treating patients with rheumatoid arthritis can be difficult because the available drugs do not treat all symptoms. However, the Vectra DA test can help physicians more quickly understand if a patient is responding or needs to switch therapies, explained Grace C. Wright, MD, PhD, clinical associate professor of medicine and attending rheumatologist at New York University Langone Medical Center.

There is a need in rheumatoid arthritis to be able to individualize treatments, but without credible and reliable biomarkers, it just isn't possible yet, said Allan Gibofsky, MD, professor of medicine and public health at Weill Cornell Medical College and an attending rheumatologist at Hospital for Special Surgery.

Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.

Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology, says that the organization has developed a number of initiatives to educate oncology practitioners on the potential of precision medicine, such as testing guidelines, online courses, a virtual tumor board, and clinical trials.

The Special Symposium on Quality at the 58th American Society of Hematology Annual Meeting & Exposition, looked at how health information technology can be utilized to improve healthcare quality, enhance patient-provider shared decision-making, and facilitate efforts in quality research.

Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).

Innovative health IT tools like those developed by Carevive help maximize the balance between patient self-management and care team engagement, which is especially important in the era of value-based care, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.

Distinct genetic signatures can help distinguish responders from nonresponders of chimeric antigen receptor (CAR) T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

Surrogate endpoints, or endpoints other than overall survival, will help accelerate drug discovery and provide additional solutions for patients, according to David Fabrizio, of Foundation Medicine, Inc. However, alternate endpoints are not without their drawbacks.

Chimeric antigen receptor (CAR) T-cells have been dramatically effective in treating B-cell cancers, according to David L. Porter, MD, of the University of Pennsylvania Health System. He also identified the use of CAR T-cells for treating solid tumors as a research area that will see more development in the coming years.

The PIONEER AF-PCI trial studied bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention with 3 different treatments. The study found that a rivaroxaban (Xarelto)-based strategy had a significant reduction of bleeding complications, explained Roxana Mehran, MD, FACC, FACP, professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.

Treat-to-target has largely become the preferred method for physicians treating patients with rheumatoid arthritis.

Gerd Burmester, MD, of Charité — Universitätsmedizin Berlin, discussed the results of a randomized, double-blind monotherapy study comparing the safety and efficacy of sarilumab with adalimumab in patients who cannot tolerate methotrexate.

At the Annual Meeting of the American College of Rheumatology in Washington, DC, several experts presented their progress in harnessing technology to help teenagers and young adults manage their juvenile arthritis.

During a session at the Annual Meeting of the American College of Rheumatology, Jeffrey Curtis, MD, discussed the ways in which patients with rheumatoid arthritis who demonstrate a less-than-adequate response to a tumor necrosis factor inhibitor can be treated with another disease-modifying antirheumatic drug.

A study inspired by a patient who could not afford his heart medication shows that there was no pattern to price variability for a common regimen to treat heart failure, which could contribute to poor adherence.

The study now includes 494 patients, and will be complete when 503 are enrolled. Of the participants, 60% required anticoagulant reversal to undergo surgery.

During a session at the Annual Meeting of the American College of Rheumatology, John D. Isaacs, MD, PhD, FRCP, not only reviewed regulatory perspectives as biosimilars enter the market, but conveyed the importance of crafting antibodies to our own purposes.